How to choose the correct cell line for producing your viral vaccine: what is important?

A.J.M. Garland, T.W.F. Pay, P.J. Radlett, The use of BHK suspension cells for the commercial production of foot and mouth disease vaccines over a twenty year period. Developments in biological standardization. ,vol. 60, pp. 163- 170 ,(1985)

M.G. Pau, C. Ophorst, M.H. Koldijk, G. Schouten, M. Mehtali, F. Uytdehaag, The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines Vaccine. ,vol. 19, pp. 2716- 2721 ,(2001) , 10.1016/S0264-410X(00)00508-9

B. Peschel, S. Frentzel, T. Laske, Y. Genzel, U. Reichl, Comparison of influenza virus yields and apoptosis-induction in an adherent and a suspension MDCK cell line Vaccine. ,vol. 31, pp. 5693- 5699 ,(2013) , 10.1016/J.VACCINE.2013.09.051

Danielle H.W. Vlecken, Ralf P.M. Pelgrim, Slawomir Ruminski, Wilfried A.M. Bakker, Leo A. van der Pol, Comparison of initial feasibility of host cell lines for viral vaccine production. Journal of Virological Methods. ,vol. 193, pp. 28- 41 ,(2013) , 10.1016/J.JVIROMET.2013.04.020

J. Seladi-Schulman, J. Steel, A. C. Lowen, Spherical Influenza Viruses Have a Fitness Advantage in Embryonated Eggs, while Filament-Producing Strains Are Selected In Vivo Journal of Virology. ,vol. 87, pp. 13343- 13353 ,(2013) , 10.1128/JVI.02004-13

Itsuki Hamamoto, Hiroshi Takaku, Masato Tashiro, Norio Yamamoto, High Yield Production of Influenza Virus in Madin Darby Canine Kidney (MDCK) Cells with Stable Knockdown of IRF7 PLoS ONE. ,vol. 8, pp. e59892- ,(2013) , 10.1371/JOURNAL.PONE.0059892

R. ten Have, Y.E. Thomassen, M.R.J. Hamzink, W.A.M. Bakker, O.E.M. Nijst, G. Kersten, G. Zomer, Development of a fast ELISA for quantifying polio D-antigen in in-process samples. Biologicals. ,vol. 40, pp. 84- 87 ,(2012) , 10.1016/J.BIOLOGICALS.2011.11.004

Audrey Le Ru, Danielle Jacob, Julia Transfiguracion, Sven Ansorge, Olivier Henry, Amine A. Kamen, Scalable production of influenza virus in HEK-293 cells for efficient vaccine manufacturing. Vaccine. ,vol. 28, pp. 3661- 3671 ,(2010) , 10.1016/J.VACCINE.2010.03.029

Ralf D. Hess, Friedemann Weber, Keith Watson, Siegfried Schmitt, Regulatory, biosafety and safety challenges for novel cells as substrates for human vaccines. Vaccine. ,vol. 30, pp. 2715- 2727 ,(2012) , 10.1016/J.VACCINE.2012.02.015

Eckard Wimmer, Steffen Mueller, Terrence M Tumpey, Jeffery K Taubenberger, Synthetic viruses: a new opportunity to understand and prevent viral disease Nature Biotechnology. ,vol. 27, pp. 1163- 1172 ,(2009) , 10.1038/NBT.1593